It's official: Pharma faces an aggressive plan for price negotiation on top brands, price-hike rollbacks and more. But does the bill stand a chance?

Months after the FDA demanded Lupin act on failures at an Indian plant, the drugmaker may have known a reckoning was coming. They were right.

Roche has spent years reprioritizing its manufacturing spending, and as part of that process, it's exiting a small molecule site in Ireland.

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

After a little more than two years on the job, Alexion CFO Paul Clancy and his “legendary caution” around transactions are out. Is an M&A spree coming?

Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.